PRS-344

N/A

Report date: 2024/12/19 13:40:41

Base Information

Drug NamePRS-344
Drug Alias NamePRS-344/ONC0055PRS-344PRS-344/S095012PRS-344S095012S-095012 +[6] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionTumor necrosis factor receptor superfamily member 9 agonistsAnti-Programmed death-ligand 1
TargetsTumor necrosis factor receptor superfamily member 9Programmed death-ligand 1
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesAustralia +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesPieris Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesServier Bio-Innovation LLCLaboratoires ServierPieris Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A